% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mai:157345,
      author       = {E. K. Mai and K. Miah$^*$ and U. Bertsch and J. Dürig and
                      C. Scheid and K. C. Weisel and C. Kunz$^*$ and M. Munder and
                      H.-W. Lindemann and M. Merz and D. Hose and A. Jauch and A.
                      Seckinger and S. Luntz and S. Sauer and S. Fuhrmann and P.
                      Brossart and A. Elmaagacli and M. Goerner and H. Bernhard
                      and M. Hoffmann and M. S. Raab and I. W. Blau and M. Hänel
                      and A. Benner$^*$ and H. J. Salwender and H. Goldschmidt},
      collaboration = {G. M. M. Group},
      title        = {{B}ortezomib-based induction, high-dose melphalan and
                      lenalidomide maintenance in myeloma up to 70 years of age.},
      journal      = {Leukemia},
      volume       = {35},
      number       = {3},
      issn         = {1476-5551},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2020-01574},
      pages        = {809-822},
      year         = {2021},
      note         = {2021 Mar;35(3):809-822},
      abstract     = {Intensive upfront therapy in newly-diagnosed multiple
                      myeloma (MM) including induction therapy (IT), high-dose
                      melphalan (MEL200), and autologous blood stem cell
                      transplantation (ASCT) followed by consolidation and/or
                      maintenance is mostly restricted to patients up to 65 years
                      of age. Prospective phase III trial data in the era of novel
                      agents for patients up to 70 years of age are not available.
                      The GMMG-MM5 trial included 601 patients between 18 and 70
                      years of age, divided in three groups for the present
                      analysis: ≤60 years (S1, n = 353), 61-65 years (S2,
                      n = 107) and 66-70 years (S3, n = 141). Treatment
                      consisted of a bortezomib-containing IT, MEL200/ASCT,
                      consolidation, and maintenance with lenalidomide. Adherence
                      to treatment was similar among patients of the three age
                      groups. Overall toxicity during all treatment phases was
                      increased in S2 and S3 compared to S1 (any adverse event/any
                      serious adverse event: $S1:81.7/41.8\%$ vs. $S2:90.7/56.5\%$
                      vs. $S3:87.2/68.1\%,$ p = 0.05/<0.001). With respect to
                      progression-free survival (log-rank p = 0.73), overall
                      survival (log-rank p = 0.54) as well as
                      time-to-progression (Gray's p = 0.83) and non-relapse
                      mortality (Gray's p = 0.25), no differences were found
                      between the three age groups. Our results imply that an
                      intensive upfront therapy with a bortezomib-containing IT,
                      MEL200/ASCT, lenalidomide consolidation, and maintenance
                      should be applied to transplant-eligible MM patients up to
                      70 years of age.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32684633},
      doi          = {10.1038/s41375-020-0976-9},
      url          = {https://inrepo02.dkfz.de/record/157345},
}